ATRA · NASDAQ
Atara Biotherapeutics (ATRA) Stock Price & Fundamentals
Atara Biotherapeutics (ATRA) closed at $1,119.55 on Oct 9, 2026, down 0.78% from the previous close of $1,128.34.
Share price, past year
1Y +3.40%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,119.55 |
| Sep 30, 2026 | $1,127.10 |
| Aug 31, 2026 | $1,157.07 |
| Jul 31, 2026 | $1,149.24 |
| Jun 30, 2026 | $1,211.95 |
| May 29, 2026 | $1,131.37 |
| Apr 30, 2026 | $1,175.86 |
| Mar 31, 2026 | $1,113.81 |
| Feb 27, 2026 | $1,144.65 |
| Jan 30, 2026 | $1,149.33 |
| Dec 31, 2025 | $1,052.55 |
| Nov 28, 2025 | $1,076.03 |
| Oct 31, 2025 | $1,074.66 |
Key statistics
- Market cap
- $10.57B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.73
- Revenue (TTM)
- $6.19M
- Net income (TTM)
- −$16.69M
- Shares outstanding
- 9.4M
- Dividend yield
- —
- 52-week range
- $1,027.43 – $1,211.95
Atara Biotherapeutics's market cap is $10.57B, based on a share price of $1,119.55 and 9.4M shares outstanding as of Jun 30, 2026.
Financials
Atara Biotherapeutics reported revenue of $120.77M for fiscal 2025, down 6.33% from fiscal 2024.
Atara Biotherapeutics earned net income of $32.69M in fiscal 2025, a net margin of 27.1%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $120.77M | −6.3% | $32.69M | 27.1% | $2.57 | −$50.94M |
| FY2024ended Dec 31, 2024 | $128.94M | +1,404.0% | −$85.40M | −66.2% | −$11.41 | −$68.96M |
| FY2023ended Dec 31, 2023 | $8.57M | −86.5% | −$276.13M | −3,220.9% | −$65.19 | −$194.20M |
| FY2022ended Dec 31, 2022 | $63.57M | — | −$228.30M | −359.1% | −$2.24 | −$274.62M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $630.00K | −$4.83M | −$0.32 |
| Q1 FY2026ended Mar 31, 2026 | $516.00K | −$4.15M | −$0.29 |
| Q4 FY2025ended Dec 31, 2025 | $1.60M | −$3.41M | −$0.80 |
| Q3 FY2025ended Sep 30, 2025 | $3.45M | −$4.30M | −$0.32 |
| Q2 FY2025ended Jun 30, 2025 | $17.58M | $2.39M | $0.19 |
| Q1 FY2025ended Mar 31, 2025 | $98.15M | $38.01M | $3.50 |
| Q4 FY2024ended Dec 31, 2024 | $32.75M | −$12.69M | $0.27 |
| Q3 FY2024ended Sep 30, 2024 | $40.19M | −$21.91M | −$2.93 |
Company profile
- Name
- Atara Biotherapeutics, Inc.
- Ticker
- ATRA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 1280 Rancho Conejo Blvd, Thousand Oaks, CA 91320
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001604464
Recent SEC filings
- Aug 12, 2026
- Aug 12, 2026
- Jun 26, 2026
- Jun 12, 2026
- May 12, 2026
- May 12, 2026
- May 7, 2026
- May 1, 2026
Frequently asked questions
What is Atara Biotherapeutics's stock price?
Atara Biotherapeutics (ATRA) closed at $1,119.55 on Oct 9, 2026, down 0.78% from the previous close of $1,128.34.
What is Atara Biotherapeutics's market cap?
Atara Biotherapeutics's market cap is $10.57B, based on a share price of $1,119.55 and 9.4M shares outstanding as of Jun 30, 2026.
How much revenue does Atara Biotherapeutics make?
Atara Biotherapeutics reported revenue of $120.77M for fiscal 2025, down 6.33% from fiscal 2024.
Does Atara Biotherapeutics pay a dividend?
Atara Biotherapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Atara Biotherapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures